|
|
Identification of new drug targets in Mycobacterium avium and Mycobacterium tuberculosis.
N. Rastogi
,
K. S. Goh
,
S. Z. van Ginkel
,
E. L. Wright
,
W. W. Barrow
Journal articles
istex
pasteur-00926642v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Immunomodulation of human peripheral blood mononuclear cell functions by defined lipid fractions of Mycobacterium avium.
W. W. Barrow
,
J. P. de Sousa
,
T. L. Davis
,
E. L. Wright
,
M. Bachelet
,
et al.
Infection and Immunity, 1993, 61 (12), pp.5286-93
Journal articles
pasteur-00925367v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Potential drug targets for Mycobacterium avium defined by radiometric drug-inhibitor combination techniques.
N. Rastogi
,
K. S. Goh
,
E. L. Wright
,
W. W. Barrow
Journal articles
pasteur-00925372v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium avium.
W. W. Barrow
,
E. L. Wright
,
K. S. Goh
,
Nalin Rastogi
Journal articles
pasteur-00925364v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Immunomodulatory spectrum of lipids associated with Mycobacterium avium serovar 8.
W. W. Barrow
,
T. L. Davis
,
E. L. Wright
,
V. Labrousse
,
M. Bachelet
,
et al.
Infection and Immunity, 1995, 63 (1), pp.126-33
Journal articles
pasteur-00925373v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Monoclonal infection involving Mycobacterium avium presenting with three distinct colony morphotypes.
E. L. Wright
,
S. Zywno-van Ginkel
,
N. Rastogi
,
W. W. Barrow
Journal of Clinical Microbiology, 1996, 34 (10), pp.2475-8
Journal articles
pasteur-00926646v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|